Early pancreatic cancer detection
Tab Title Description
Describes the nature of a clinical study. Types include:
- Observational study — observes people and measures outcomes without affecting results.
- Interventional study (clinical trial) — studies new tests, treatments, drugs, surgical procedures or devices.
- Medical records research — uses historical information collected from medical records of large groups of people to study how diseases progress and which treatments and surgeries work best.
- Jacksonville, Florida: 20-005478
About this study
The primary purpose of this study is to standardize the collection of demographic, clinical, and imaging data, and biosamples for a large high-risk familial Pancreatic Ductal Adenocarinoma (PDAC) cohort at consortium clinical cancer centers, worldwide.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.
- Individuals between 18 and 90 years of age.
Cohort 1 - Individuals without history of Pancreatic Ductal Adenocarcinoma (PDAC) meeting any of the following criteria:
- 2+ relatives with PDAC on same side of family where 2 affected are first degree related to each other and at least 1 affected is first degree related to subject; age 50+ or ≤ 10 years younger than earliest PDAC in family at time of diagnosis.
- 2 affected first degree relatives with PDAC; age 50+ or 10 years younger than earliest PDAC in family.
- BRCA1, BRCA2, PALB2, ATM, MLH1, MSH2, MSH6, PMS2, EPCAM pathogenic or likely pathogenic variant AND 1 first or second degree relative with PDAC; age 50+ or 10 years younger than earliest PDAC in family.
- Familial Atypical Moles and Malignant Melanoma (FAMMM) with pathogenic or likely pathogenic CDKN2A variant; age 40+.
- Peutz-Jegher syndrome with STK11 pathogenic or likely pathogenic variant; age 35+.
- Hereditary pancreatitis with PRSS1 pathogenic or likely pathogenic variant and history of pancreatitis; age 40+.
Cohort 2 - Individuals without history of PDAC meeting any of the following criteria:
- ATM, BRCA1, BRCA2, or PALB2 pathogenic or likely pathogenic variant regardless of family history, age 50+.
- 2+ relatives with PDAC on the same side of family, any degree of relation, not meeting other criteria above; age 50+ or 10 years younger than earliest PDAC in family.
- 1 FDR with PDAC ≤ age 45; age up to 10 years younger than PDAC diagnosis in family member.
Cohort 3 - Individual meeting criteria for Cohorts 1 or 2 EXCEPT age (i.e., too young to qualify for Cohorts 1 or 2).
Cohort 4 - Individuals without history of PDAC presenting for evaluation who do not meet any criteria above after collection of full family history and/or germline testing.
Cohort 5 - Individuals who are not otherwise engaged in pancreas surveillance at a participating site may be invited to participate in the PRECEDE database and to donate a biosample (e.g., blood, saliva, and/or buccal swab) for discovery studies. This may include relatives of individuals in Cohorts 1-4 and individuals with personal history of PDAC.
- Individuals not meeting any single Inclusion Criteria.
Participating Mayo Clinic locations
Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.
|Mayo Clinic Location
Mayo Clinic principal investigator
Yan Bi, M.D., Ph.D.
Open for enrollment
Yan Bi M.D., Ph.D.
Publications are currently not available